← Back to Search

Neuromodulation Device

InterStim Micro for Overactive Bladder (ELITE Trial)

N/A
Waitlist Available
Research Sponsored by MedtronicNeuro
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

ELITE Trial Summary

This trial will assess the long-term safety and performance of a device used to treat urinary incontinence.

Who is the study for?
This trial is for adults who need sacral neuromodulation therapy, can complete study tasks, and have specific diagnoses of bowel incontinence or overactive bladder as shown by diaries. Pregnant women, those with certain neurological conditions, mechanical urinary obstructions, or recent botulinum toxin therapy are excluded.Check my eligibility
What is being tested?
The InterStim Micro System's safety and performance for treating urinary retention, bowel incontinence, and overactive bladder are being studied. This post-market follow-up aims to confirm the long-term outcomes of this treatment.See study design
What are the potential side effects?
While not explicitly listed here, side effects may include discomfort at the implant site, potential nerve injury from device placement or stimulation-related issues such as pain or changes in bowel/bladder function.

ELITE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline for HRQL Total Score
Change From Baseline in CCIS Score
Change From Baseline in the Number of CISC/Day

ELITE Trial Design

3Treatment groups
Experimental Treatment
Group I: Overactive Bladder CohortExperimental Treatment1 Intervention
Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
Group II: Non-Obstructive Urinary Retention CohortExperimental Treatment1 Intervention
Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
Group III: Fecal Incontinence CohortExperimental Treatment1 Intervention
Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.

Find a Location

Who is running the clinical trial?

MedtronicNeuroLead Sponsor
69 Previous Clinical Trials
20,671 Total Patients Enrolled
4 Trials studying Urinary Retention
923 Patients Enrolled for Urinary Retention
Mylène ChampsStudy DirectorMedtronic

Media Library

InterStim Micro (Neuromodulation Device) Clinical Trial Eligibility Overview. Trial Name: NCT04506866 — N/A
Urinary Retention Research Study Groups: Overactive Bladder Cohort, Fecal Incontinence Cohort, Non-Obstructive Urinary Retention Cohort
Urinary Retention Clinical Trial 2023: InterStim Micro Highlights & Side Effects. Trial Name: NCT04506866 — N/A
InterStim Micro (Neuromodulation Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04506866 — N/A
~31 spots leftby Jun 2025